[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
March 1999

High-Dose Trimethoprim-Sulfamethoxazole Therapy With Corticosteroids in Previously Intolerant Patients With AIDS-Associated Pneumocystis carinii Pneumonia

Author Affiliations

Not Available

Arch Dermatol. 1999;135(3):350-351. doi:10-1001/pubs.Arch Dermatol.-ISSN-0003-987x-135-3-dlt0399

High-dose therapy with the combination drug trimethoprim-sulfamethoxazole for the treatment of patients with Pneumocystis carinii pneumonia (PCP) is usually contraindicated in trimethoprim-sulfamethoxazole–intolerant patients with acquired immunodeficiency syndrome (AIDS). However, clinicians may have to reintroduce trimethoprim-sulfamethoxazole at high dosages to treat these patients with PCP. In those circumstances, prescribing drugs such as corticosteroids, which will decrease the risk of adverse cutaneous reaction, is desirable. Corticosteroids significantly reduced the incidence of adverse reaction to trimethoprim-sulfamethoxazole during treatment of patients with AIDS-associated PCP in 4 studies.1-4